8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  February 1, 2017

Glaukos Corporation

(Exact name of registrant as specified in its charter)

Delaware	001-37463	33-0945406
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

229 Avenida Fabricante San Clemente, California	92672
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (949) 367-9600

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) On February 1, 2017, Glaukos Corporation (the “Company”) announced that Chris M. Calcaterra has been appointed as its Chief Operating Officer, effective immediately.  Mr. Calcaterra has served as the Company’s Chief Commercial Officer since 2008, and was a “named executive officer” in the Company’s Proxy Statement for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission on April 19, 2016 (the “2015 Proxy Statement”).  Mr. Calcaterra’s business experience and other information can be found in the 2015 Proxy Statement.

In connection with this appointment, Mr. Calcaterra’s annual base salary has been increased to $385,000, and he is eligible for an annual target bonus of up to 50% of his base salary, based upon achievement of certain Company and individual performance objectives.  All other terms of Mr. Calcaterra’s employment, including severance benefits, will remain consistent with the terms set forth in his Offer Letter dated July 10, 2014 and his Executive Severance and Change in Control Agreement dated July 10, 2014, both included as exhibits 10.17 and 10.18, respectively, to the Company’s Report on Form 10-K for the year ended December 31, 2015 filed with the Securities and Exchange Commission on March 15, 2016.

A copy of the press release issued by the Company announcing Mr. Calcaterra’s appointment is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

Exhibit  Number	Description
99.1	Press release of Glaukos Corporation, dated February 1, 2017.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLAUKOS CORPORATION (Registrant)
By:	/s/ Richard L. Harrison
	Name:	Richard L. Harrison
	Title:	Chief Financial Officer

Date: February 1, 2017

2

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Media Contact:

Cassandra Dump

(619) 971-1887

cassy@pascalecommunications.com

Investor Contact:

Sheree Aronson

VP, Investor Relations

(949) 367-9600 ext 371

saronson@glaukos.com

GLAUKOS CORPORATION PROMOTES CHRIS M. CALCATERRA TO CHIEF OPERATING OFFICER

San Clemente, CA — February 1, 2017 — Glaukos  Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that Chris M. Calcaterra has been named Chief Operating Officer, effective immediately.

Mr. Calcaterra joined Glaukos in 2008 and has served as its Chief Commercial Officer since that time.  With his promotion to Chief Operating Officer, Mr. Calcaterra will continue to lead the company’s global sales, marketing and reimbursement functions, while adding oversight of manufacturing operations, facilities management and clinical recruiting to his management responsibilities.

Mr. Calcaterra has more than 25 years of experience in the ophthalmic medical technology industry.  Prior to joining Glaukos, he was a senior vice president responsible for the cataract business at Advanced Medical Optics, Inc. (AMO), which was acquired by Abbott Laboratories in 2009.  He previously held increasingly responsible leadership positions in a variety of sales and marketing roles at AMO, as well as AMO’s predecessor surgical division business at Allergan, Inc.

“Chris has been instrumental in the growth and development of Glaukos since joining our management team nearly nine years ago and I am confident that he will continue to play an integral role in our success in the newly created Chief Operating Officer position,” said Thomas Burns, Glaukos President and Chief Executive Officer.  “His sales and marketing prowess, thoughtful leadership, sound judgement, competitive spirit and stellar reputation across the ophthalmic professional community and industry make him an ideal individual for this expanded leadership responsibility.  On behalf of the entire Glaukos organization, I am pleased to offer Chris this promotion and our congratulations and full support.”

Mr. Calcaterra holds a bachelor’s degree from Miami University and a master’s in business administration from Xavier University.

1

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness.  The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm.  Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression.  The company believes the iStent, measuring 1.0 mm long and 0.33 mm wide, is the smallest medical device ever approved by the FDA.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements.  Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release.  These potential risks and uncertainties include, without limitations, our ability to continue to pioneer the worldwide development and expansion of MIGs and products for the treatment of glaucoma.  These risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016 filed with the Securities and Exchange Commission. Our filings with the Securities and Exchange Commission are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov.  In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com.  All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements.  You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof.  We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

##

2